Compare Adaptive Biotechnologies Corp (ADPT) vs Aon PLC (AON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Aon PLC — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Aon PLC trades at $360.46 (market cap $76.85B). The key difference: Aon PLC is far larger — about 23.1× Adaptive Biotechnologies Corp's market cap, and Aon PLC pays a 0.91% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AON | |
|---|---|---|
Market Cap | $3.33B | $76.85B |
Sector | Health | Financials |
52-Week High | $22.37 | $375.27 |
52-Week Low | $10.24 | $308.22 |
Enterprise Value | $3.19B | $90.91B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AON trades at $359.82, up 0.66% with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 22.54% net income margin and 46.82% ROE, supported by revenue growth to $17.18B in 2025. Analyst consensus is a Buy with a $385.50 price target, and the company continues to innovate with initiatives like the Aon DPX platform launch in 2026.
Outlook remains positive driven by AI integration and strategic growth, though risks include debt levels and market volatility. The stock offers upside potential near consensus targets, but investors should monitor execution of the 3x3 plan and competitive pressures in the insurance brokerage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →
